Sibel Ucpinar, Patrick F. Smith, Li Long, Fujun Li, Hui Yan, Jyoti Wadhwa, . . . Mengyao Li. (2023). Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants. Wiley.
Chicago Style (17th ed.) CitationSibel Ucpinar, et al. Rilzabrutinib, a Reversible Covalent Bruton's Tyrosine Kinase Inhibitor: Absorption, Metabolism, Excretion, and Absolute Bioavailability in Healthy Participants. Wiley, 2023.
MLA (9th ed.) CitationSibel Ucpinar, et al. Rilzabrutinib, a Reversible Covalent Bruton's Tyrosine Kinase Inhibitor: Absorption, Metabolism, Excretion, and Absolute Bioavailability in Healthy Participants. Wiley, 2023.
Warning: These citations may not always be 100% accurate.